
    
      This is an expanded access program in which the drug being tested is called pevonedistat,
      which is used in combination with azcitidine. This study will provide expanded access of
      pevonedistat (in combination with azacitidine) for the first-line treatment to participants
      with HR-MDS and option of real world data (RWD) collection for the benefit of future
      participants.

      All participants will receive azacitidine via intravenous or subcutaneous route in
      combination with pevonedistat intravenous infusion.

      This multi-center trial will be conducted win the United States. Participant will continue
      treatment until benefit is no longer derived from the treatment (that is, until disease
      progression, or treatment is no longer tolerable), the benefit-risk no longer favors the
      individual, an appropriate alternative therapy becomes available, the patient chooses to
      discontinue the treatment, or pevonedistat becomes commercially available.
    
  